
On Tuesday, PTC Therapeutics Inc (NASDAQ:PTCT) revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
The study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.